C12N 2760/00041
Use of virus, viral particle or viral elements as a vector
C12N2760/00041 (Use of virus, viral particle or viral elements as a vector) appears on 11 US grants and 13 published applications in this corpus.
Search patents in C12N- Granted patents
- 11
- Published applications
- 13
- Assignees
- 10
- Inventors
- 35
- Latest grant
- 11 Nov 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 3 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 1 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 1 | 2 |
| 2017 | 0 | 1 |
| 2018 | 1 | 1 |
| 2019 | 0 | 2 |
| 2020 | 0 | 1 |
| 2021 | 2 | 1 |
| 2022 | 2 | 1 |
| 2023 | 0 | 0 |
| 2024 | 0 | 1 |
| 2025 | 1 | 0 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/00043Viral genome or elements thereof as genetic vectorIndexing code9
- C12N 2760/00042Virus or viral particle as vehicleIndexing code2
- C12N 2760/00044Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code1
- C12N 2760/00045Special targeting system for viral vectorsIndexing code1
Recent patents
- Recombinant AAV vectors useful for reducing immunity against transgene products11 Nov 2025US 12,467,063 B2University of Massachusetts
- Enhanced expression of RNA vectors27 Dec 2022US 11,534,417 B2The University Court of the University of Edinburgh
- Borna viral vector and use thereof23 Aug 2022US 11,421,247 B2Kyoto University
- IL6R block CAR-T transgenic vector for alleviating CRS, preparation method thereof20 Jul 2021US 11,066,680 B2Shanghai Unicar-Therapy Bio-Medicine Technology Co., Ltd
- Recombinant AAV vectors useful for reducing immunity against transgene products13 Apr 2021US 10,975,391 B2University of Massachusetts
- Recombinant aav vectors useful for reducing immunity against transgene products18 Jun 2026US 2026/0167990 A1University of Massachusetts
- Pharmaceutical composition utilizing bornavirus vector24 Oct 2024US 2024/0350668 A1Kyoto University
- Method for rescuing influenza virus and composition therefor10 Feb 2022US 2022/0041997 A1Zhejiang Senwei Biomedical Development Co., Ltd
- Recombinant aav vectors useful for reducing immunity against transgene products14 Oct 2021US 2021/0317475 A1University of Massachusetts
- Borna viral vector and use thereof30 Apr 2020US 2020/0131531 A1Kyoto University
Most cited
By later US patents
- Recombinant AAV vectors useful for reducing immunity against transgene products2US 10,975,391 B2University of Massachusetts · 2021
- Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases2US 6,015,660 AThe Regents of the University of California · 2000
- Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases2US 6,077,510 AThe Regents of the University of California · 2000
- Calcium formate as a supplement to prevent neural tube defects2US 9,895,328 B2Board of Regents, The University of Texas System · 2018
- IL6R block CAR-T transgenic vector for alleviating CRS, preparation method thereof1US 11,066,680 B2Shanghai Unicar-Therapy Bio-Medicine Technology Co., Ltd · 2021